Haite Biotech announced that the company signed an exclusive cooperation and licensing agreement with Visara for the HT006.2.2 eye drops project, and Visara obtained exclusive rights for this product outside of Greater China. After the agreement comes into effect, Visara will pay an initial payment of 7 million US dollars and recent milestone payments; Haite Biotech can also collect relevant milestone payments of up to US$104 million according to the clinical development and commercialization process, and collect a certain percentage of royalties based on annual net sales within the authorized region.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.